May 1 |
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
|
May 1 |
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
|
Apr 16 |
Aileron Therapeutics GAAP EPS of -$1.54 misses by $1.37
|
Apr 15 |
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 12 |
Aileron Therapeutics announces CEO transition
|
Mar 12 |
Aileron Therapeutics Announces CEO Transition
|
Feb 15 |
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
|
Feb 1 |
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
|
Jan 29 |
Aileron Therapeutics files to sell 7.06M shares for holders
|